抑制PI3Kα阻断了骨质突变原生体的特异性和超炎性反应,以防止异型骨化
José Antonio Valer1, Alexandre Deber1, Marius Wits2
1Departament de Ciències Fisiològiques, Universitat de Barcelona, IDIBELL, C/ Feixa Llarga s/n 08907 Hospitalet de Llobregat, Barcelona, Spain.
eLife
|June 17, 2025
概括
脂氨醇3-酶α (PI3Kα) 抑制剂,如药物BYL719,在防止异型骨化 (HO) 中表现有前途. 这种疗法即使在受伤后几天也有效,准了参与HO发展的关键细胞过程.
科学领域:
- 生物医学科学 生物医学科学
- 药理学 药理学是指药理学的学科.
- 再生医学是一种再生医学.
背景情况:
- 不同类型的骨化 (HO) 是创伤后或在遗传条件下,如纤维发育不良骨质渐进症 (FOP) 后的异常骨形成.
- 之前的研究表明,酸氨基醇3-酶α (PI3Kα) 抑制剂是HO的潜在治疗策略.
研究的目的:
- 确认PI3Kα抑制剂的疗效,特别是BYL719 (Alpelisib/Piqray),用于治疗HO.
- 为了阐明作用机制,并优化在HO中BYL719的管理时间.
- 评估BYL719对ACVR1和FOP相关突变的直接影响.
主要方法:
- 在细胞培养和小鼠模型中使用了BYL719HO.
- 研究PI3Kα抑制对骨性质原生体特异性和炎症反应的影响.
- 对HO病变进行了时间过程测试,以评估BYL719对细胞过程和炎症标志物的影响.
主要成果:
- BYL719有效地预防HO,即使在受伤后3-7天内服用,有效性也保持不变.
- 治疗效果主要通过PI3Kα抑制在目标上,而不会直接影响ACVR1或ACVR1R206H激酶活性.
- 在受伤部位的原始细胞中PI3Kα的缺乏足以防止HO.
- BYL719 抑制骨质突变原生因子的特异化,减少炎症,抑制单细胞和巨细胞的迁移,增殖和促炎性细胞因子表达.
结论:
- 用BYL719抑制PI3Kα是一种安全有效的治疗方法,用于异型骨化.
- BYL719解决了HO病变的细胞分化和炎症成分.
- 药物的有效性和最佳时间为管理HO提供了一个有希望的临床策略.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Bone Formation by Endochondral Ossification
5.4K
Bone formation, or ossification, begins around the sixth to seventh week of embryonic development. Most bones develop from a cartilaginous template through the process of endochondral ossification. Cartilage formation begins when clusters of mesenchymal cells differentiate into chondrocytes. These chondrocytes proliferate rapidly and secrete an extracellular matrix that becomes encased in a membrane called the perichondrium. The resulting cartilage model provides a template that resembles the...
5.4K


